<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3765">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01335724</url>
  </required_header>
  <id_info>
    <org_study_id>862-P-201</org_study_id>
    <nct_id>NCT01335724</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Diclofenac 1.16% Gel in Subjects With Acute Neck Pain</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Multi-center Parallel Group Phase IV Study to Evaluate the Efficacy and Safety of Diclofenac 1.16% Gel in Subjects With Acute Neck Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of diclofenac 1.16% gel
      compared with placebo applied four times a day in subjects with acute neck pain.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Pain on Movement</measure>
    <time_frame>48 h</time_frame>
    <safety_issue>No</safety_issue>
    <description>Pain on movement on a 100 mm visual analog scale. Minimum score =0 mm &quot;no pain&quot;. Maximum score =100 mm &quot;extreme pain&quot;.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain at Rest</measure>
    <time_frame>96h</time_frame>
    <safety_issue>No</safety_issue>
    <description>Pain at Rest on a 100 mm visual analog scale. Minimum score =0 mm &quot;no pain&quot;. Maximum score =100 mm &quot;extreme pain&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neck Disability Index</measure>
    <time_frame>96h</time_frame>
    <safety_issue>No</safety_issue>
    <description>Neck Disability Index total score. Minimum = 0 &quot;Best&quot;. Maximum = 50 &quot;Worst&quot;</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Neck Pain</condition>
  <arm_group>
    <arm_group_label>Diclofenac diethylamine 1.16% gel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo gel</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diclofenac diethylamine 1.16% gel</intervention_name>
    <description>Diclofenac diethylamine 1.16% gel</description>
    <arm_group_label>Diclofenac diethylamine 1.16% gel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo gel</intervention_name>
    <description>Placebo gel</description>
    <arm_group_label>placebo gel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subjects, age range 18 and over.

          -  Patient with acute neck pain meeting baseline pain intensity level and duration

        Exclusion Criteria:

          -  Pain medication was taken within the 6 hours that precede randomization.

          -  Patient with chronic neck pain as defined as pain for 3 months or longer

          -  Any neck pain that is attributable to any organic disease, such as prolapsed disc,
             spondylolisthesis, osteomalacia, inflammatory arthritis, metabolic, neurological
             diseases or tumors.

          -  Any recent strains of the neck muscles documented by the clinical evaluation and
             anamnesis
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>NCH investigative site</name>
      <address>
        <city>Cologne</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NCH investigative site</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NCH investigative site</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <lastchanged_date>June 14, 2012</lastchanged_date>
  <firstreceived_date>April 13, 2011</firstreceived_date>
  <firstreceived_results_date>May 11, 2012</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neck Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diclofenac</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Diclofenac Diethylamine 1.16% Gel</title>
        </group>
        <group group_id="P2">
          <title>Placebo Gel</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Diclofenac Diethylamine 1.16% Gel</title>
        </group>
        <group group_id="B2">
          <title>Placebo Gel</title>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="36"/>
                <measurement group_id="B2" value="36"/>
                <measurement group_id="B3" value="72"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="36"/>
                <measurement group_id="B2" value="34"/>
                <measurement group_id="B3" value="70"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="2"/>
                <measurement group_id="B3" value="2"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="29.8" spread="10.5"/>
                <measurement group_id="B2" value="37.8" spread="15.2"/>
                <measurement group_id="B3" value="33.8" spread="13.6"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="19"/>
                <measurement group_id="B2" value="14"/>
                <measurement group_id="B3" value="33"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="17"/>
                <measurement group_id="B2" value="22"/>
                <measurement group_id="B3" value="39"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Germany</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="36"/>
                <measurement group_id="B2" value="36"/>
                <measurement group_id="B3" value="72"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pain on Movement</title>
        <description>Pain on movement on a 100 mm visual analog scale. Minimum score =0 mm &quot;no pain&quot;. Maximum score =100 mm &quot;extreme pain&quot;.</description>
        <time_frame>48 h</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Diclofenac Diethylamine 1.16% Gel</title>
          </group>
          <group group_id="O2">
            <title>Placebo Gel</title>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="36"/>
                  <measurement group_id="O2" value="36"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Pain on Movement</title>
            <description>Pain on movement on a 100 mm visual analog scale. Minimum score =0 mm &quot;no pain&quot;. Maximum score =100 mm &quot;extreme pain&quot;.</description>
            <units>mm</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="19.5" spread="12.9"/>
                  <measurement group_id="O2" value="56.9" spread="16.1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain at Rest</title>
        <description>Pain at Rest on a 100 mm visual analog scale. Minimum score =0 mm &quot;no pain&quot;. Maximum score =100 mm &quot;extreme pain&quot;.</description>
        <time_frame>96h</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Diclofenac Diethylamine 1.16% Gel</title>
          </group>
          <group group_id="O2">
            <title>Placebo Gel</title>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="36"/>
                  <measurement group_id="O2" value="36"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Pain at Rest</title>
            <description>Pain at Rest on a 100 mm visual analog scale. Minimum score =0 mm &quot;no pain&quot;. Maximum score =100 mm &quot;extreme pain&quot;.</description>
            <units>mm</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1.2" spread="2.9"/>
                  <measurement group_id="O2" value="19.2" spread="11.9"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neck Disability Index</title>
        <description>Neck Disability Index total score. Minimum = 0 &quot;Best&quot;. Maximum = 50 &quot;Worst&quot;</description>
        <time_frame>96h</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Diclofenac Diethylamine 1.16% Gel</title>
          </group>
          <group group_id="O2">
            <title>Placebo Gel</title>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="36"/>
                  <measurement group_id="O2" value="36"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Neck Disability Index</title>
            <description>Neck Disability Index total score. Minimum = 0 &quot;Best&quot;. Maximum = 50 &quot;Worst&quot;</description>
            <units>Total Score</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="2.8" spread="3.0"/>
                  <measurement group_id="O2" value="14.6" spread="6.8"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Diclofenac Diethylamine 1.16% Gel</title>
        </group>
        <group group_id="E2">
          <title>Placebo Gel</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2.00</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Preliminary agreement between Novartis Consumer Health and the investigator</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical project Leader</name_or_title>
      <organization>Novartis Consumer Health</organization>
      <phone>+41223635528</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>
